NASDAQ
Vivani Medical, Inc. (VANI)
♥ 607 Thanks from members
Vivani Medical, Inc. (VANI) exhibits a mixed yet cautiously optimistic market profile, underpinned by its Phase 1 SLIM-1 trial of NPM-139, a non-exclusive evaluation agreement with Novo Nordisk, and an average analyst price target implying significant upside despite zero current revenue.